Comparative Pharmacology
Head-to-head clinical analysis: BASAGLAR versus LANTUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BASAGLAR versus LANTUS.
BASAGLAR vs LANTUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glargine is a recombinant human insulin analog with a prolonged duration of action due to precipitation at the injection site, providing a constant basal insulin supply. It binds to the insulin receptor, activating downstream signaling pathways that promote glucose uptake, glycogen synthesis, and lipogenesis while inhibiting gluconeogenesis and glycogenolysis.
Long-acting recombinant human insulin analog that binds to insulin receptors, activating downstream signaling pathways to facilitate glucose uptake, inhibit gluconeogenesis, and regulate lipid and protein metabolism.
Subcutaneous injection, initial dose 0.2-0.4 units/kg/day, titrated to target glycemic control; typical maintenance 0.5-1.0 units/kg/day
Subcutaneous injection once daily at the same time each day. Initial dose: 0.2-0.4 units/kg/day. Titrate based on blood glucose monitoring.
None Documented
None Documented
13.2 hours (range 10.0-20.6 hours) for insulin glargine; reflects extended duration after subcutaneous injection.
Terminal half-life: 24 hours (provides basal insulin coverage for 24 hours)
Renal: minimal (<1% as unchanged drug); hepatic metabolism to inactive metabolites; fecal: not significant.
Renal: minimal (degraded by insulin-degrading enzyme), biliary: negligible, fecal: negligible
Category C
Category C
Long-acting Insulin
Long-acting Insulin